ALIOF News Alert Actelion Ltd (ALIOF) 116.0765 10/01/2014 00
Post# of 273327
Posted On: 10/01/2014 1:27:42 AM
Actelion Ltd (ALIOF) 116.0765 $ALIOF
Acute Inflammation Therapeutics Pipeline Report 2014 - 9 Companies & 10 Drug Profiles
M2 - Wed Sep 10, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/849tzx/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Actelion Ltd - Forest Laboratories, Inc. - Italfarmaco S.p.A. - Alligator Bioscience AB - Anacor Pharmaceuticals, Inc. - Omeros Corporation - Dompe Farmaceutici S.p.A. - Peptinnovate Limited Drug Profiles - ACT-389949 - ATL-1222 - CGEN-856 - ADC-1004 - DF-2156A - Selective Inhibitor of Pro Inflammatory Cytokine - AN-3485 - PIN-201104 - Small Molecule Targeting GPR32 for Acute Inflammation - Distamycin Derivatives For more information visit http://www.researchandmarkets.com/research/849tzx/acute
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.
Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:34PM CDT
Gilead (GILD) received a favorable verdict on Sovaldi.
TrovaGene (TROV) Worth Watching: Stock Rises 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:39AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as its shares rose almost 9% on the day.
NewLink Genetics Corp. (NLNK) Jumps: Stock Adds 8.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose almost 9% on the day.
Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:44AM CDT
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares gain nearly 10% on the day.
Epizyme (EPZM) Crumbles: Stock Falls by 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:33AM CDT
Epizyme has been witnessing a flat movement in its earnings estimate front and its share price has been declining for past 24 hours
Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:20PM CDT
Amgen (AMGN) suffered a major setback when its phase III study, FOCUS on multiple myeloma treatment, Kyprolis did not meet its primary endpoint.
Genomic Health Raised to Buy on Better-than-Expected Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 11:10AM CDT
Genomic Health's (GHDX) sales grossed $70.5 million, up 10.7% year over year, exceeding the Zacks Consensus Estimate of $69 million
Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.
Insmed Incorporated (INSM) in Focus: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:39AM CDT
Insmed Incorporated (INSM) was a big mover last session, as its shares rose nearly 11% on the day.
InterMune (ITMN) Jumps: Stock Adds 14.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:51AM CDT
InterMune, Inc. (ITMN) was a big mover last session, as its shares rose over 14% on the day.
Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 1:37PM CDT
Shares of Dendreon Corporation (DNDN) were down significantly after the company warned that it will not be able to repay or refinance its notes due 2016.
BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:02PM CDT
Shares of BioDelivery Sciences International, Inc. (BDSI) jumped 7.58 % after the company reported its second-quarter 2014 results.
Myriad Genetics' Q4 Earnings Beat Estimates, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:40AM CDT
In the fourth quarter, Myriad Genetics' (MYGN) total revenue climbed 8.4% year over year to $188.8 million, beating the Zacks Consensus Estimate of $187 million by a whisker.
Intercept Pharmaceuticals (ICPT) Worth Watching: Stock Gains 16.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:25AM CDT
Intercept Pharmaceuticals (ICPT) was a big mover last session, with shares rising nearly 17% on the day.
Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:20PM CDT
Regeneron's (REGN) Eylea has been approved for a third indication in the EU.
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:49PM CDT
Sarepta reported second quarter loss of 85 cents per share compared to a loss of 60 cents per share in the year-ago quarter.
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents
Acute Inflammation Therapeutics Pipeline Report 2014 - 9 Companies & 10 Drug Profiles
M2 - Wed Sep 10, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/849tzx/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Actelion Ltd - Forest Laboratories, Inc. - Italfarmaco S.p.A. - Alligator Bioscience AB - Anacor Pharmaceuticals, Inc. - Omeros Corporation - Dompe Farmaceutici S.p.A. - Peptinnovate Limited Drug Profiles - ACT-389949 - ATL-1222 - CGEN-856 - ADC-1004 - DF-2156A - Selective Inhibitor of Pro Inflammatory Cytokine - AN-3485 - PIN-201104 - Small Molecule Targeting GPR32 for Acute Inflammation - Distamycin Derivatives For more information visit http://www.researchandmarkets.com/research/849tzx/acute
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.
Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:34PM CDT
Gilead (GILD) received a favorable verdict on Sovaldi.
TrovaGene (TROV) Worth Watching: Stock Rises 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:39AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as its shares rose almost 9% on the day.
NewLink Genetics Corp. (NLNK) Jumps: Stock Adds 8.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose almost 9% on the day.
Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:44AM CDT
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares gain nearly 10% on the day.
Epizyme (EPZM) Crumbles: Stock Falls by 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:33AM CDT
Epizyme has been witnessing a flat movement in its earnings estimate front and its share price has been declining for past 24 hours
Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:20PM CDT
Amgen (AMGN) suffered a major setback when its phase III study, FOCUS on multiple myeloma treatment, Kyprolis did not meet its primary endpoint.
Genomic Health Raised to Buy on Better-than-Expected Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 11:10AM CDT
Genomic Health's (GHDX) sales grossed $70.5 million, up 10.7% year over year, exceeding the Zacks Consensus Estimate of $69 million
Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.
Insmed Incorporated (INSM) in Focus: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:39AM CDT
Insmed Incorporated (INSM) was a big mover last session, as its shares rose nearly 11% on the day.
InterMune (ITMN) Jumps: Stock Adds 14.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:51AM CDT
InterMune, Inc. (ITMN) was a big mover last session, as its shares rose over 14% on the day.
Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 1:37PM CDT
Shares of Dendreon Corporation (DNDN) were down significantly after the company warned that it will not be able to repay or refinance its notes due 2016.
BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:02PM CDT
Shares of BioDelivery Sciences International, Inc. (BDSI) jumped 7.58 % after the company reported its second-quarter 2014 results.
Myriad Genetics' Q4 Earnings Beat Estimates, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:40AM CDT
In the fourth quarter, Myriad Genetics' (MYGN) total revenue climbed 8.4% year over year to $188.8 million, beating the Zacks Consensus Estimate of $187 million by a whisker.
Intercept Pharmaceuticals (ICPT) Worth Watching: Stock Gains 16.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:25AM CDT
Intercept Pharmaceuticals (ICPT) was a big mover last session, with shares rising nearly 17% on the day.
Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:20PM CDT
Regeneron's (REGN) Eylea has been approved for a third indication in the EU.
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:49PM CDT
Sarepta reported second quarter loss of 85 cents per share compared to a loss of 60 cents per share in the year-ago quarter.
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents
(0)
(0)